{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:49:56Z","timestamp":1744793396937,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yungjin Pharm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Upon withdrawal of propacetamol, an injectable formulation of the paracetamol prodrug, in Europe due to safety concerns, South Korea\u2019s regulatory body requested a post-marketing surveillance study exploring its safety profile. We characterized regional disparities in adverse events (AE) associated with propacetamol between Asia and Europe using the World Health Organization\u2019s pharmacovigilance database, VigiBase. We performed disproportionality analyses using reporting odds ratios (rOR) and information component (IC) to determine whether five AEs (anaphylaxis, Stevens\u2013Johnson syndrome, thrombosis, contact dermatitis\/eczema, injection site reaction [ISR]) were associated with propacetamol versus non-propacetamol injectable antipyretics in Asia and Europe, separately. In Asia, there was a high reporting ratio of propacetamol-related ISR (rOR 5.72, 95% CI 5.19\u20136.31; IC<jats:sub>025<\/jats:sub> 1.27), satisfying the signal criteria; there were no reports of thrombosis and contact dermatitis\/eczema. Two signals were identified in Europe, with higher reporting ratios for thrombosis (rOR 7.45, 95% CI 5.19\u201310.71; IC<jats:sub>025<\/jats:sub> 1.92) and contact dermatitis\/eczema (rOR 16.73, 95% CI 12.48\u201322.42; IC<jats:sub>025<\/jats:sub> 2.85). Reporting ratios of propacetamol-related anaphylaxis were low for Asia and Europe. While signals were found for thrombosis and contact dermatitis\/eczema in Europe, these were not detected in Asia. These findings suggest potential ethnic differences in propacetamol-related AEs between Asia and Europe, which could serve as supportive data for future decision-making.<\/jats:p>","DOI":"10.1038\/s41598-022-26211-0","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T18:03:00Z","timestamp":1670954580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A study of the regional differences in propacetamol-related adverse events using VigiBase data of the World Health Organization"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-0941","authenticated-orcid":false,"given":"Han Eol","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-6553","authenticated-orcid":false,"given":"Sungho","family":"Bea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-0789","authenticated-orcid":false,"given":"Dongwon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Mok","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhee","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-1715","authenticated-orcid":false,"given":"Young-Min","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-0071","authenticated-orcid":false,"given":"Jae-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"26211_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1399-6576.2006.00971.x","volume":"50","author":"D Hynes","year":"2006","unstructured":"Hynes, D., McCarroll, M. & Hiesse-Provost, O. Analgesic efficacy of parenteral paracetamol (propacetamol) and diclofenac in post-operative orthopaedic pain. Acta Anaesthesiol. Scand. 50, 374\u2013381. https:\/\/doi.org\/10.1111\/j.1399-6576.2006.00971.x (2006).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"26211_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007126.pub2","author":"A Tzortzopoulou","year":"2011","unstructured":"Tzortzopoulou, A. et al. Single dose intravenous propacetamol or intravenous paracetamol for postoperative pain. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD007126.pub2 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"26211_CR3","unstructured":"European Medicines Agency, Meeting highlights from the Committee for Medicinal Products for Human Use, 21\u201324 September 2009. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/meeting-highlights-committee-medicinal-products-human-use-21-24-september-2009_en.pdf. Accessed 23 Apr 2022."},{"key":"26211_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000245982","volume":"195","author":"A Barbaud","year":"1997","unstructured":"Barbaud, A. et al. Occupational contact dermatitis to propacetamol. Allergological and chemical investigations in two new cases. Dermatology 195, 329\u2013331. https:\/\/doi.org\/10.1159\/000245982 (1997).","journal-title":"Dermatology"},{"key":"26211_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/s0140-6736(95)92743-3","volume":"346","author":"A Barbaud","year":"1995","unstructured":"Barbaud, A., Trechot, P., Bertrand, O. & Schmutz, J. L. Occupational allergy to propacetamol. Lancet 346, 902. https:\/\/doi.org\/10.1016\/s0140-6736(95)92743-3 (1995).","journal-title":"Lancet"},{"key":"26211_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1600-0536.1998.tb05704.x","volume":"38","author":"V Berl","year":"1998","unstructured":"Berl, V., Barbaud, A. & Lepoittevin, J. P. Mechanism of allergic contact dermatitis from propacetamol: Sensitization to activated N,N-diethylglycine. Contact Dermatitis 38, 185\u2013188. https:\/\/doi.org\/10.1111\/j.1600-0536.1998.tb05704.x (1998).","journal-title":"Contact Dermatitis"},{"key":"26211_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/jpet.116.233452","volume":"359","author":"F Schillers","year":"2016","unstructured":"Schillers, F., Eberhardt, E., Leffler, A. & Eberhardt, M. Propacetamol-induced injection pain is associated with activation of transient receptor potential Vanilloid 1 channels. J. Pharmacol. Exp. Ther. 359, 18\u201325. https:\/\/doi.org\/10.1124\/jpet.116.233452 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"26211_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1600-0536.1996.tb02392.x","volume":"35","author":"C Szczurko","year":"1996","unstructured":"Szczurko, C., Dompmartin, A., Michel, M., Castel, B. & Leroy, D. Occupational contact dermatitis from propacetamol. Contact Dermatitis 35, 299\u2013301. https:\/\/doi.org\/10.1111\/j.1600-0536.1996.tb02392.x (1996).","journal-title":"Contact Dermatitis"},{"key":"26211_CR9","first-page":"18","volume":"9","author":"KJ Sun","year":"2017","unstructured":"Sun, K. J. et al. Analysis of adverse drug reactions related analgesics collected by spontaneous reporting program within a hospital. J. Pharmacoepidemiol. Risk Manage. 9, 18\u201326 (2017).","journal-title":"J. Pharmacoepidemiol. Risk Manage."},{"key":"26211_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3904\/kjm.2017.92.4.392","volume":"92","author":"Y Seo","year":"2017","unstructured":"Seo, Y. et al. Clinical features of serious adverse drug reactions in a tertiary care hospital in Korea. Korean J. Med. 92, 392\u2013400 (2017).","journal-title":"Korean J. Med."},{"key":"26211_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pds.4159","volume":"26","author":"HY Lee","year":"2017","unstructured":"Lee, H. Y. et al. Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiol. Drug Saf. 26, 256\u2013264. https:\/\/doi.org\/10.1002\/pds.4159 (2017).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"26211_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12887-018-1166-z","volume":"18","author":"SJ Choi","year":"2018","unstructured":"Choi, S. J. et al. The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: A multicenter, randomized, double-blind, comparative, phase 3 clinical trial. BMC Pediatr. 18, 201. https:\/\/doi.org\/10.1186\/s12887-018-1166-z (2018).","journal-title":"BMC Pediatr."},{"key":"26211_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000246286","volume":"193","author":"AL De Coninck","year":"1996","unstructured":"De Coninck, A. L. et al. Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances. Dermatology 193, 338\u2013341. https:\/\/doi.org\/10.1159\/000246286 (1996).","journal-title":"Dermatology"},{"key":"26211_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/bja\/aer107","volume":"106","author":"ED McNicol","year":"2011","unstructured":"McNicol, E. D. et al. Single-dose intravenous paracetamol or propacetamol for prevention or treatment of postoperative pain: A systematic review and meta-analysis. Br. J. Anaesth. 106, 764\u2013775. https:\/\/doi.org\/10.1093\/bja\/aer107 (2011).","journal-title":"Br. J. Anaesth."},{"key":"26211_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1460-9592.2004.01518.x","volume":"15","author":"I Murat","year":"2005","unstructured":"Murat, I. et al. Tolerance and analgesic efficacy of a new iv paracetamol solution in children after inguinal hernia repair. Paediatr. Anaesth. 15, 663\u2013670. https:\/\/doi.org\/10.1111\/j.1460-9592.2004.01518.x (2005).","journal-title":"Paediatr. Anaesth."},{"key":"26211_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.18549\/PharmPract.2017.03.931","volume":"15","author":"E Cheema","year":"2017","unstructured":"Cheema, E., Haseeb, A., Khan, T. M., Sutcliffe, P. & Singer, D. R. Barriers to reporting of adverse drugs reactions: A cross sectional study among community pharmacists in United Kingdom. Pharm. Pract. (Granada) 15, 931. https:\/\/doi.org\/10.18549\/PharmPract.2017.03.931 (2017).","journal-title":"Pharm. Pract. (Granada)"},{"key":"26211_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1124\/jpet.117.242107","volume":"362","author":"MH Court","year":"2017","unstructured":"Court, M. H. et al. Race, gender, and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American volunteers. J. Pharmacol. Exp. Ther. 362, 431\u2013440. https:\/\/doi.org\/10.1124\/jpet.117.242107 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"26211_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/FPC.0000000000000150","volume":"25","author":"LL Mazaleuskaya","year":"2015","unstructured":"Mazaleuskaya, L. L. et al. PharmGKB summary: Pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet. Genom. 25, 416\u2013426. https:\/\/doi.org\/10.1097\/FPC.0000000000000150 (2015).","journal-title":"Pharmacogenet. Genom."},{"key":"26211_CR19","first-page":"4","volume":"279","author":"RB Kim","year":"1996","unstructured":"Kim, R. B. et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J. Pharmacol. Exp. Ther. 279, 4\u201311 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"942","key":"26211_CR20","doi-asserted-by":"publisher","first-page":"e945","DOI":"10.1016\/j.ajem.2015.10.044","volume":"34","author":"J Benmoussa","year":"2016","unstructured":"Benmoussa, J., Chevenon, M., Nandi, M., Forlenza, T. J. & Nfonoyim, J. Ibuprofen-induced thrombotic thrombocytopenic purpura. Am. J. Emerg. Med. 34(942), e945-947. https:\/\/doi.org\/10.1016\/j.ajem.2015.10.044 (2016).","journal-title":"Am. J. Emerg. Med."},{"key":"26211_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092\u20131102. https:\/\/doi.org\/10.1056\/NEJMoa050493 (2005).","journal-title":"N. Engl. J. Med."},{"key":"26211_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13256-019-2097-5","volume":"13","author":"JP Lara","year":"2019","unstructured":"Lara, J. P. et al. Diclofenac-induced thrombotic thrombocytopenic purpura with concomitant complement dysregulation: A case report and review of the literature. J. Med. Case Rep. 13, 190. https:\/\/doi.org\/10.1186\/s13256-019-2097-5 (2019).","journal-title":"J. Med. Case Rep."},{"key":"26211_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier, N. A. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa050330 (2005).","journal-title":"N. Engl. J. Med."},{"key":"26211_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5114\/ceji.2017.72822","volume":"42","author":"H Szymanik-Grzelak","year":"2017","unstructured":"Szymanik-Grzelak, H., Przychodzen, J., Stelmaszczyk-Emmel, A. & Panczyk-Tomaszewska, M. Thrombotic thrombocytopenic purpura in the course of systemic lupus erythematosus in a 15-year-old girl. Cent. Eur. J. Immunol. 42, 407\u2013408. https:\/\/doi.org\/10.5114\/ceji.2017.72822 (2017).","journal-title":"Cent. Eur. J. Immunol."},{"key":"26211_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","volume":"66","author":"ML Kowalski","year":"2011","unstructured":"Kowalski, M. L. et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)\u2014classification, diagnosis and management: Review of the EAACI\/ENDA(#) and GA2LEN\/HANNA*. Allergy 66, 818\u2013829. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02557.x (2011).","journal-title":"Allergy"},{"key":"26211_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-0536.1993.tb04536.x","volume":"29","author":"PD Pigatto","year":"1993","unstructured":"Pigatto, P. D. et al. Topical NSAID allergic contact dermatitis. Italian experience. Contact Dermatitis 29, 39\u201341. https:\/\/doi.org\/10.1111\/j.1600-0536.1993.tb04536.x (1993).","journal-title":"Contact Dermatitis"},{"key":"26211_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.iac.2012.12.002","volume":"33","author":"KM Woessner","year":"2013","unstructured":"Woessner, K. M. & Castells, M. NSAID single-drug-induced reactions. Immunol. Allergy Clin. N. Am. 33, 237\u2013249. https:\/\/doi.org\/10.1016\/j.iac.2012.12.002 (2013).","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"26211_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/DER.0000000000000119","volume":"26","author":"A Goldenberg","year":"2015","unstructured":"Goldenberg, A. & Jacob, S. E. Demographics of US pediatric contact dermatitis registry providers. Dermatitis 26, 184\u2013188. https:\/\/doi.org\/10.1097\/DER.0000000000000119 (2015).","journal-title":"Dermatitis"},{"key":"26211_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MCP.0b013e3281eb8ef0","volume":"13","author":"CR Keenan","year":"2007","unstructured":"Keenan, C. R. & White, R. H. The effects of race\/ethnicity and sex on the risk of venous thromboembolism. Curr. Opin. Pulm. Med. 13, 377\u2013383. https:\/\/doi.org\/10.1097\/MCP.0b013e3281eb8ef0 (2007).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"26211_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1034\/j.1600-0536.2002.470504.x","volume":"47","author":"SP Modjtahedi","year":"2002","unstructured":"Modjtahedi, S. P. & Maibach, H. I. Ethnicity as a possible endogenous factor in irritant contact dermatitis: Comparing the irritant response among Caucasians, blacks, and Asians. Contact Dermatitis 47, 272\u2013278. https:\/\/doi.org\/10.1034\/j.1600-0536.2002.470504.x (2002).","journal-title":"Contact Dermatitis"},{"key":"26211_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","volume":"39","author":"HH Ampadu","year":"2016","unstructured":"Ampadu, H. H. et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: Analyses of spontaneous reports in VigiBase(R). Drug Saf. 39, 335\u2013345. https:\/\/doi.org\/10.1007\/s40264-015-0387-4 (2016).","journal-title":"Drug Saf."},{"key":"26211_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2019.03.002","volume":"113","author":"E Guerrero","year":"2019","unstructured":"Guerrero, E. et al. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. Eur. J. Cancer 113, 10\u201313. https:\/\/doi.org\/10.1016\/j.ejca.2019.03.002 (2019).","journal-title":"Eur. J. Cancer"},{"key":"26211_CR33","doi-asserted-by":"publisher","first-page":"104509","DOI":"10.1016\/j.yrtph.2019.104509","volume":"109","author":"D MaciasSaint-Gerons","year":"2019","unstructured":"MaciasSaint-Gerons, D., BoscoCortez, F., JimenezLopez, G., Castro, J. L. & Tabares-Seisdedos, R. Cataracts and statins. A disproportionality analysis using data from VigiBase. Regul. Toxicol. Pharmacol. 109, 104509. https:\/\/doi.org\/10.1016\/j.yrtph.2019.104509 (2019).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"26211_CR34","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/bcp.13693","volume":"84","author":"J Mahe","year":"2018","unstructured":"Mahe, J. et al. Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase. Br. J. Clin. Pharmacol. 84, 2373\u20132383. https:\/\/doi.org\/10.1111\/bcp.13693 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"26211_CR35","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40264-018-0693-8","volume":"41","author":"TTH Nguyen","year":"2018","unstructured":"Nguyen, T. T. H., Roussin, A., Rousseau, V., Montastruc, J. L. & Montastruc, F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological-pharmacodynamic study in VigiBase((R)). Drug Saf. 41, 1087\u20131096. https:\/\/doi.org\/10.1007\/s40264-018-0693-8 (2018).","journal-title":"Drug Saf."},{"key":"26211_CR36","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9 (2018).","journal-title":"Lancet Oncol."},{"key":"26211_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-199819010-00001","volume":"19","author":"S Olsson","year":"1998","unstructured":"Olsson, S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 19, 1\u201310. https:\/\/doi.org\/10.2165\/00002018-199819010-00001 (1998).","journal-title":"Drug Saf."},{"key":"26211_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist, M. VigiBase, the WHO global ICSR database system: Basic facts. Drug Inf. J. 42, 409\u2013419 (2008).","journal-title":"Drug Inf. J."},{"key":"26211_CR39","unstructured":"Ministry of Food and Drug Safety, South Korea, Medications Approval History\u2014Propacetamol. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=199500674. Accessed 10 Nov 2022."},{"key":"26211_CR40","unstructured":"French Health Product Safety Agency, Commission nationale de pharmacovigilance. compte rendu de la r\u00e9union dumardi 7 juillet 2009. https:\/\/archiveansm.integra.fr\/var\/ansm_site\/storage\/original\/application\/83e6e90a48d5beba0556099fa00be94d.pdf. Accessed 10 Nov 2022."},{"key":"26211_CR41","unstructured":"US Food and Drug Administration, What is a Serious Adverse Event? 2016. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 23 Oct 2022."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26211-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26211-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26211-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T18:04:58Z","timestamp":1670954698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26211-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["26211"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26211-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Park SM and Jeon J are employees of Yungjin Pharm. Shin JY received grants from the Ministry of Food and Drug Safety, the Ministry of Health and Welfare, the National Research Foundation of South Korea, and pharmaceutical companies, including Daiichi Sankyo, GSK, and Pfizer, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21568"}}